Mochtar Riady Institute for


With a population of over 220 Million, public health is one serious concern in Indonesia. Cancer in particular is a leading cause of deaths. Early diagnosis and effective treatment are keys for the control and management of this complex systemic disease, in which the research in Indonesia is still in its infancy.

As part of Lippo Medical and Health Program, that includes the Faculty of Medicine Pelita Harapan University, Siloam Hospitals and the Mochtar Riady Comprehensive Cancer Center (MRCCC), Mochtar Riady Institute for Nanotechnology (MRIN) is established in 2006 to support cancer research in Indonesia using both genomic and proteomic approaches.


  • To become an internationally recognized research center in the field of nanomedicines focusing on oncology.
  • To improve the nation's quality and competency in the field of nanomedicines through quality education and scientific discovery.
  • To foster research and education in the field on nanomedicines through interdisciplinary research partnerships and collaborations


To conduct innovative research on cancer prevention and new understandings of the cause, early diagnosis, control and cure of cancer.


Latest News

Congratulations to Dr. Andi Utama and Team.
Friday, August 12, 2011

Congratulation to Dr. Andi Utama and team for new publication in journal of Medical Virology "Low Prevalence of Hepatitis B Virus Pre-S Deletion Mutation in Indonesia ".

Link Source

Congratulations to Dr. Ivet Suriapranata and Team.
Tuesday, June 07, 2011

Congratulation to Dr. Ivet Suriapranata and team for new publication in BMC Medical Genetics "Genetic factors associated with patients-specific warfarin dose in ethnic Indonesians".

Link Source

Copyright © 2021 Mochtar Riady Institute. All rights reserved.